Visipaque 270

(iodixanol)

ApprovedSmall molecule

GGE Healthcare

Visipaque 270 is one of 287 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

286

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseCompleted

HypothyroidismWithdrawn

ToxicityUnknown status

Lung CancerActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

Myocardial InfarctionActive, not recruiting

Pancreatic CancerActive, not recruiting

PreoperativeCompleted

Renal InsufficiencyCompleted

Coronary Artery DiseaseApproved

Completed

HypothyroidismApproved

Withdrawn

ToxicityApproved

Unknown status

Lung CancerPreclinical

Active, not recruiting

Acute Myocardial InfarctionApproved

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

PreoperativePreclinical

Completed

Renal InsufficiencyApproved

Completed

Competition

Competitive Landscape

306 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Visipaque 270

GGE Healthcare

Approved

1 2

Byetta

AstraZeneca

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness2 trials

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Terminated·GGE Healthcare·Phase 3·NCT00335335·89 enrolled

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Terminated·GGE Healthcare·Phase 3·NCT00348608·66 enrolled

Toxicity2 trials

Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction

Unknown status·YYong Huo·Phase 4·NCT01580046·200 enrolled

Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients

Terminated·GGuangdong Provincial People's Hospital·Phase 4·NCT01402219·204 enrolled

Imaging1 trial

Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

Completed·GGE Healthcare·Phase 4·NCT01376089·304 enrolled

ART1 trial

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

Completed·GGE Healthcare·Phase 4·NCT01475097·255 enrolled

Acute Myocardial Infarction1 trial

Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·OOspedale San Donato·Phase 4·NCT00827788·432 enrolled

10 more indications

Myocardial Infarction1 trial

Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium

Completed·GGE Healthcare··NCT03671603·2,755 enrolled

Pancreatic Cancer1 trial

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Terminated·SStanford University··NCT01326364·6 enrolled

MPA1 trial

A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients

Completed·—·Phase 4·NCT00926562·592 enrolled

Lung Cancer1 trial

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Terminated·SStanford University·N/A·NCT01188486·12 enrolled

Preoperative1 trial

DynaCT in Preoperative Imaging Before Insertion of Stentgraft

Completed·NNorwegian University of Science and Technology·N/A·NCT01146639·20 enrolled

Fibrinolysis1 trial

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Completed·NNYU Langone Health·Phase 4·NCT01848899·100 enrolled

Renal insufficiency1 trial

RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography

Completed·SSeoul National University Hospital·Phase 4·NCT00247325

Hypothyroidism1 trial

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Withdrawn·GGE Healthcare·Phase 4·NCT03631771

Coronary Artery Disease1 trial

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

Completed·MMinneapolis Heart Institute Foundation·Approved·NCT05065073·62 enrolled

Unspecified2 trials

Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients

Terminated·BBracco Diagnostics, Inc·Phase 4·NCT00782639·23 enrolled

Isovue in Peripheral Digital Subtraction Angiography (DSA)

Completed·BBracco Diagnostics, Inc·Phase 4·NCT01075217·174 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 22, 1996

VISIPAQUE 270

NDA NDA020351

Aug 29, 1997

VISIPAQUE 270

NDA NDA020808

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for iodixanol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iodixanol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iodixanol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020808). U.S. Food & Drug Administration.
[5]
SEC EDGAR — GE Healthcare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGE Healthcare

Visipaque 270

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness2 trials

Toxicity2 trials

Imaging1 trial

ART1 trial

Acute Myocardial Infarction1 trial

Myocardial Infarction1 trial

Pancreatic Cancer1 trial

MPA1 trial

Lung Cancer1 trial

Preoperative1 trial

Fibrinolysis1 trial

Renal insufficiency1 trial

Hypothyroidism1 trial

Coronary Artery Disease1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News